Overview

Gemcitabine (GFF) in Patients With Pancreatic Cancer

Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the efficacy and safety of the drug combination GFF in patients with advanced pancreatic cancer (APC).
Phase:
Phase 2
Details
Lead Sponsor:
CONKO-Studiengruppe
Collaborator:
Eli Lilly and Company
Treatments:
Folic Acid
Gemcitabine
Leucovorin
Levoleucovorin